scholarly journals Qualification of National Cancer Institute–Designated Cancer Centers for Quantitative PET/CT Imaging in Clinical Trials

2017 ◽  
Vol 58 (7) ◽  
pp. 1065-1071 ◽  
Author(s):  
Joshua S. Scheuermann ◽  
Janet S. Reddin ◽  
Adam Opanowski ◽  
Paul E. Kinahan ◽  
Barry A. Siegel ◽  
...  
Keyword(s):  
Clinical Trials ◽  
National Cancer Institute ◽  
Ct Imaging ◽  
Cancer Centers ◽  
Quantitative Pet ◽  
Pet Ct

scholarly journals 18F-FDG-PET/CT Imaging in Advanced Glottic Cancer: A Tool for Clinical Decision in Comparison with Conventional Imaging

2019 ◽  
Vol 2019 ◽  
pp. 1-12
Author(s):  
G. Paone ◽  
F. Martucci ◽  
V. Espeli ◽  
L. Ceriani ◽  
G. Treglia ◽  
...  
Keyword(s):  
Fdg Pet ◽  
False Negative ◽  
Ct Imaging ◽  
Radiotherapy Planning ◽  
Glottic Cancer ◽  
Conventional Imaging ◽  
Prognostic Information ◽  
Quantitative Pet ◽  
Pet Ct ◽  
Fdg Pet Ct

This study assessed the role of 18F-FDG PET-CT (PET/CT) to detect the cartilage and paraglottic infiltration in advanced glottic cancer comparing the results with those of conventional imaging (CI) (contrast-enhanced computed tomography and/or magnetic resonance). In addition, we assessed the prognostic value of quantitative parameters, measured on baseline PET/CT, in terms of event-free survival (EFS) and overall survival (OS). We retrospectively analyzed 27 patients with glottic squamous cell carcinoma stage III and IVA, treated in our institute between 2010 and 2016, comparing PET/CT, performed for staging and radiotherapy planning, and CI findings. Cohen’s K was used to compare concordance between PET/CT and CI. Imaging findings were correlated with endoscopic evaluation and histological reports (gold standard (GS)). All lesions shown by CI were also detected by PET/CT imaging, and in 5 cases, a better definition of local infiltration was achieved with PET/CT than CI (5 CT). Sensitivity, specificity, and accuracy of PET/CT and CT were 95%, 86%, and 93% and 70%, 86%, and 74% for, respectively. MRI showed sensitivity and specificity of 100%. One false-negative (FN) cases and 1 false-positive (FP) case were observed with PET/CT with no difference compared to MRI (10 cases). Six FN cases and 1 FP case were observed with CT. Cohen’s K was 0.60 (PET vs. CI) and 0.80 (PET vs. GS). Patients were followed-up for at least 24 months to calculate EFS and OS. 13 local recurrence and 7 deaths were recorded. Among quantitative PET parameters, baseline MTV was the most powerful predictor of outcome. Our data suggest a reliable sensitivity and accuracy of PET/CT in the evaluation of local extension, proving a useful method for initial local staging in addition to the well-established role in lymph-node and distant sites assessment. Furthermore, pretreatment MTV provides better prognostic information than other PET/CT parameters.

scholarly journals Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute–Designated Cancer Program

2016 ◽  
Vol 12 (4) ◽  
pp. e396-e404 ◽  
Author(s):  
Kalyan C. Mantripragada ◽  
Adam J. Olszewski ◽  
Andrew Schumacher ◽  
Kimberly Perez ◽  
Ariel Birnbaum ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Next Generation Sequencing ◽  
National Cancer Institute ◽  
Next Generation ◽  
Genomic Alterations ◽  
Cancer Centers ◽  
Cancer Program ◽  
Clinical Trial Accrual ◽  
Generation Sequencing

Purpose: Successful clinical trial accrual targeting uncommon genomic alterations will require broad national participation from both National Cancer Institute (NCI)–designated comprehensive cancer centers and community cancer programs. This report describes the initial experience with clinical trial accrual after next-generation sequencing (NGS) from three affiliated non–NCI-designated cancer programs. Materials and Methods: Clinical trial participation was reviewed after enrollment of the first 200 patients undergoing comprehensive genomic profiling by NGS as part of an institutional intuitional review board–approved protocol at three affiliated hospitals in Rhode Island and was compared with published experience from NCI-designated cancer centers. Results: Patient characteristics included a median age of 64 years, a median of two lines of prior therapy, and a predominance of GI carcinomas (58%). One hundred sixty-four of 200 patients (82%) had adequate tumor for NGS, 95% had genomic alterations identified, and 100% had variants of unknown significance. Fifteen of 164 patients (9.2%) enrolled in genotype-directed clinical trials, and three patients (1.8%) received commercially available targeted agents off clinical trials. The reasons for nonreceipt of NGS-directed therapy were no locally available matching trial (48.6%), ineligibility (33.6%) because of comorbidities or interim clinical deterioration, physician's choice of a different therapy (6.8%), or stable disease (11%). Conclusion: This experience demonstrates that a program enrolling patients in specific targeted agent clinical trials after NGS can be implemented successfully outside of the NCI-designated cancer program network, with comparable accrual rates. This is important because targetable genes have rare mutation rates and clinical trial accrual after NGS is low.

Transconvolution and the virtual positron emission tomograph-A new method for cross calibration in quantitative PET/CT imaging

2013 ◽  
Vol 40 (6Part1) ◽  
pp. 062503 ◽  
Author(s):  
George A. Prenosil ◽  
Thilo Weitzel ◽  
Michael Hentschel ◽  
Bernd Klaeser ◽  
Thomas Krause
Keyword(s):  
Ct Imaging ◽  
New Method ◽  
Positron Emission Tomograph ◽  
Quantitative Pet ◽  
Positron Emission ◽  
Pet Ct ◽  
Cross Calibration

scholarly journals Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials

2015 ◽  
Vol 56 (6) ◽  
pp. 955-961 ◽  
Author(s):  
M. M. Graham ◽  
R. L. Wahl ◽  
J. M. Hoffman ◽  
J. T. Yap ◽  
J. J. Sunderland ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Fdg Pet ◽  
Ct Imaging ◽  
Pet Ct ◽  
Oncology Clinical Trials ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Early-Phase Clinical Trials In The Community: Results From the National Cancer Institute Community Cancer Centers Program Early-Phase Working Group Baseline Assessment

2013 ◽  
Vol 9 (2) ◽  
pp. e55-e61 ◽  
Author(s):  
Howard A. Zaren ◽  
Suresh Nair ◽  
Ronald S. Go ◽  
Rebecca A. Enos ◽  
Keith S. Lanier ◽  
...  
Keyword(s):  
Clinical Trials ◽  
National Cancer Institute ◽  
Early Phase ◽  
Working Group ◽  
Baseline Assessment ◽  
Cancer Centers ◽  
Early Phase Trials ◽  
Critical Components ◽  
Early Phase Clinical Trials

The authors conclude that community cancer centers are capable of conducting early-phase trials; infrastructure and collaborations are critical components of success.

Sign in / Sign up

Export Citation Format

Share Document